MKI67 and gastrointestinal stromal tumor: Zhao et al12 reported that the Ki67 index (≤5, 5‐8, and >8%) was an independent predictor related to recurrence‐free survival of GIST patients; a Ki67 index >8% can supplement the modified NIH criteria for distinguishing different outcomes in high‐risk GIST patients and unfavorable response to imatinib adjuvant therapy.